Dr. Reddy’s Laboratories Ltd., a leading Indian pharmaceutical company, has entered into a strategic collaboration with Alvotech, a global biotech firm specializing in biosimilar medicines. The partnership aims to co-develop, manufacture, and commercialize a biosimilar version of Keytruda® (pembrolizumab), a groundbreaking cancer treatment used for multiple cancer types worldwide.
Keytruda® is a highly successful immunotherapy drug, with global sales reaching an impressive US$29.5 billion in 2024. By combining their expertise, Dr. Reddy’s and Alvotech plan to accelerate the biosimilar’s development timeline and expand its availability across international markets.
Under the agreement, both companies will share development costs and responsibilities, ensuring efficient manufacturing and distribution. Each partner retains the right to commercialize the biosimilar globally, with certain exceptions, maximizing reach and impact.
“We are very pleased to enter into this collaboration for pembrolizumab with Dr. Reddy’s. This agreement demonstrates Alvotech’s ability to leverage its dedicated R&D and manufacturing platform for biosimilars, accelerating the expansion of our pipeline by pursuing growing global markets. It further enables us to increase the availability of cost-effective, critical biologic medications to patients world-wide,” said Róbert Wessman, chairman and CEO of Alvotech.
